Not found

Dan Gombos, MD

Associate Affiliate Member, Research Institute
Houston Methodist


After completing his postdoctoral training in London, UK, Dr. Gombos returned to The University of
Texas M.D. Anderson Cancer Center (MDACC) in Houston, Texas as an Assistant Professor in 2001. He also joined the faculty at The University of Texas Medical Branch in Galveston, Texas in 2005 as a Clinical Assistant Professor of Ophthalmology and Visual Sciences. Dr. Gombos became an Associate Professor at MDACC in 2007, and a Clinical Associate Professor at The University of Texas Medical Branch in 2008. At MDACC, he is currently developing a comprehensive program for the management of patients with intra and periocular tumors. The program will also include special services for children with intraocular retinoblastoma. Dr. Gombos was also a founding physician in the Retinoblastoma Center of Houston, a collaborative effort between The Methodist Hospital, Baylor College of Medicine, Texas Children's Hospital, and MDACC that provides a comprehensive treatment program for retinoblastoma patients and conducts groundbreaking research to improve diagnostic methods and treatment and public awareness campaigns to promote early detection.

Description of Research

Dr. Gombos' research involves clinical trials that use proton beam radiation therapy or gene transfer therapy for pediatric refractory retinoblastoma.

Areas Of Expertise

Retinoblastoma Intraocular tumors Radiation therapy Gene transfer

A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231)
Jubran, RF, Villablanca, JG, Krailo, M, Piao, J, Huang, L, Murphree, AL, OBrien, J, Gombos, D, Shields, CL, Meadows, A & Chintagumpala, M 2020, , Pediatric Blood and Cancer, vol. 67, no. 9, e28502.

Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic
Consortium members & MD Anderson Head and Neck Surgery Treatment Guidelines Consortium 2020, , Head and Neck, vol. 42, no. 6, pp. 1194-1201.

Ocular Pathology Recommendations during COVID-19 from the American Association of Ophthalmic Oncologists and Pathologists (AAOOP)
Chévez-Barrios, P, Milman, T, Grossniklaus, HE, Folberg, R, Salomão, DR & Gombos, DS 2020, , Ocular Oncology and Pathology, vol. 6, no. 3, pp. 223-224.

Considerations for the Management and Triage of Ocular Oncology Cases during the COVID-19 Pandemic
Skalet, AH, Allen, RC, Shields, CL, Wilson, MW, Mruthyunjaya, P & Gombos, DS 2020, , Ocular Oncology and Pathology, vol. 6, no. 3, pp. 219-222.

Immune-Related Oral, Otologic, and Ocular Adverse Events
Srivastava, A, Al-Zubidi, N, Appelbaum, E, Gombos, DS, Nader, ME, Gidley, PW & Chambers, MS 2020, . in Advances in Experimental Medicine and Biology. vol. 1244, Advances in Experimental Medicine and Biology, vol. 1244, Springer, pp. 295-307.

Technical and anatomical factors affecting intra-arterial chemotherapy fluoroscopy time and radiation dose for intraocular retinoblastoma
Area, C, Yen, CJ, Chévez-Barrios, P, Herzog, C, Kan, P, Zheng, W, Lin, F, Chintagumpala, M, Gombos, D & Chen, SR 2019, , Journal of neurointerventional surgery, vol. 11, no. 12, pp. 1273-1276.

Pilot study of circulating tumor cells in early-stage and metastatic uveal melanoma
Anand, K, Roszik, J, Gombos, D, Upshaw, J, Sarli, V, Meas, S, Lucci, A, Hall, C & Patel, S 2019, , Cancers, vol. 11, no. 6, 856.

Erratum: Ocular toxicities associated with targeted anticancer agents: An analysis of clinical data with management suggestions (Oncotarget (2017) 8 (58709-58727) DOI: 10.18632/oncotarget.17634)
Fu, C, Gombos, D, Lee, J, George, GC, Hess, K, Whyte, A & Hong, DS 2019, Oncotarget, vol. 10, no. 9, pp. 1011-1013.

Adjuvant ipilimumab in high-risk Uveal melanoma
Fountain, E, Bassett, RL, Cain, S, Posada, L, Gombos, DS, Hwu, P, Bedikian, A & Patel, SP 2019, , Cancers, vol. 11, no. 2, 152.

Proceedings of the association for research in vision and ophthalmology and champalimaud foundation ocular oncogenesis and oncology conference
Smith, JR, Pe’er, J, Belfort, RN, Cardoso, F, Carvajal, RD, Carvalho, C, Coupland, SE, Desjardins, L, Francis, JH, Gallie, BL, Gombos, D, Grossniklaus, HE, Heegaard, S, Jager, MJ, Kaliki, S, Ksander, B, Maeurer, M, Moreno, E, Pulido, JS, Ryll, B, Singh, AD, Zhao, J, Parreira, A, Wilson, DJ & O’brien, JM 2019, , Translational Vision Science and Technology, vol. 8, no. 1, 9.

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma
Tavera, RJ, Forget, MA, Kim, YU, Sakellariou-Thompson, D, Creasy, CA, Bhatta, A, Fulbright, OJ, Ramachandran, R, Thorsen, ST, Flores, E, Wahl, A, Gonzalez, AM, Toth, C, Wardell, S, Mansaray, R, Radvanyi, LG, Gombos, DS, Patel, SP, Hwu, P, Amaria, RN, Bernatchez, C & Haymaker, C 2018, , Journal of Immunotherapy, vol. 41, no. 9, pp. 399-405.

Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial
Jonasch, E, McCutcheon, IE, Gombos, DS, Ahrar, K, Perrier, ND, Liu, D, Robichaux, CC, Villarreal, MF, Weldon, JA, Woodson, AH, Pilie, PG, Fuller, GN, Waguespack, SG & Matin, SF 2018, , The Lancet Oncology, vol. 19, no. 10, pp. 1351-1359.

Skalet, AH, Gombos, DS, Gallie, BL, Kim, JW, Shields, CL, Marr, BP, Plon, SE & Chévez-Barrios, P 2018, , Ophthalmology, vol. 125, no. 9, pp. e64-e65.

DICER1 Syndrome: Characterization of the Ocular Phenotype in a Family-Based Cohort Study
Huryn, LA, Turriff, A, Harney, LA, Carr, AG, Chevez-Barrios, P, Gombos, DS, Ram, R, Hufnagel, RB, Hill, DA, Zein, WM, Schultz, KAP, Bishop, R & Stewart, DR 2019, , Ophthalmology, vol. 126, no. 2, pp. 296-304.

Metastatic Melanoma of the Optic Nerve Sheath
D’souza, NM, Nguyen, HD, Smith, SV, Nagarajan, P, Diab, A, Allen, RC, Gombos, D & Lee, AG 2018, , Neuro-Ophthalmology, vol. 42, no. 3, pp. 187-190.

Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group
Friedman, DL, Krailo, M, Villaluna, D, Gombos, D, Langholz, B, Jubran, R, Shields, C, Murphree, L, OBrien, J, Kessel, S, Rodriguez-Galindo, C, Chintagumpala, M & Meadows, AT 2017, , Pediatric Blood and Cancer, vol. 64, no. 7, e26394.

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study
Qin, Y, Petaccia de Macedo, M, Reuben, A, Forget, MA, Haymaker, C, Bernatchez, C, Spencer, CN, Gopalakrishnan, V, Reddy, S, Cooper, ZA, Fulbright, OJ, Ramachandran, R, Wahl, A, Flores, E, Thorsen, ST, Tavera, RJ, Conrad, C, Williams, MD, Tetzlaff, MT, Wang, WL, Gombos, DS, Esmaeli, B, Amaria, RN, Hwu, P, Wargo, JA, Lazar, AJ & Patel, SP 2017, , OncoImmunology, vol. 6, no. 6, e1321187.

Neuro-ophthalmologic manifestations of cholangiocarcinoma: A case series
Rico, G, Smith, SV, Siddiqui, Y, Whyte, A, Gombos, D & Lee, AG 2017, , Eye (Basingstoke), vol. 31, no. 8, pp. 1245-1248.

Vitreous Seeds in Retinoblastoma: Clinicopathologic Classification and Correlation
Amram, AL, Rico, G, Kim, JW, Chintagumpala, M, Herzog, CE, Gombos, D & Chévez-Barrios, P 2017, , Ophthalmology, vol. 124, no. 10, pp. 1540-1547.

Ocular toxicities associated with targeted anticancer agents: An analysis of clinical data with management suggestions
Fu, C, Gombos, D, Lee, J, George, GC, Hess, K, Whyte, A & Hong, DS 2017, , Oncotarget, vol. 8, no. 35, pp. 58709-58727.